Praxis Precision Medicines (PRAX) COO discloses share and option stake

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) filed an initial ownership report for Chief Operating Officer Megan Sniecinski as of January 1, 2026. She beneficially owns 20,877 shares of common stock, which include unvested restricted stock units that settle in common shares. In addition, she holds multiple stock options covering blocks of common stock at exercise prices ranging from $31.8 to $257.25, with vesting schedules spanning several years and expirations extending to 2035. All reported holdings are listed as directly owned.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sniecinski Megan

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	20,877(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	12/01/2031	Common Stock	11,999	$257.25	D
Stock Option (Right to Buy)	(3)	06/22/2032	Common Stock	821	$31.8	D
Stock Option (Right to Buy)	(4)	01/12/2033	Common Stock	9,999	$44.4	D
Stock Option (Right to Buy)	(5)	01/12/2034	Common Stock	30,000	$43.37	D
Stock Option (Right to Buy)	(6)	07/29/2034	Common Stock	36,400	$56.94	D
Stock Option (Right to Buy)	(7)	01/10/2035	Common Stock	22,500	$63.15	D

Explanation of Responses:

1. Includes: (i) 5,805 unvested Restricted Stock Units ("RSUs") from an award of 7,800 RSUs granted on July 29, 2024, which vests in equal annual installments over a four-year period beginning on January 12, 2025; and (ii) 11,250 RSUs granted on January 10, 2025, which vests in equal annual installments over a four-year period beginning on January 10, 2026. The RSUs may be settled only by delivering shares of the Issuer's common stock, and thus, both grants are being reported in Table 1 as allowed per SEC guidance.

2. This option is fully vested.

3. The shares underlying this stock option vest over a four-year period, with 25% vested on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

4. The shares underlying this stock option vest over a four-year period, with 25% vested on January 12, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

5. The shares underlying this stock option vest as follows: 50% vested in full on January 12, 2024 (the "Grant Date") and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on the first anniversary of the Grant Date and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

6. The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the reporting person's continued service through each vesting date.

7. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 10, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filing for PRAX disclose about insider Megan Sniecinski?

The Form 3 shows that Chief Operating Officer Megan Sniecinski beneficially owns 20,877 shares of common stock and several stock option awards, all reported as directly owned.

How many PRAX common shares does the COO report owning on Form 3?

The COO reports beneficial ownership of 20,877 shares of Praxis Precision Medicines common stock, including unvested restricted stock units that will settle in shares.

What stock options are reported by the PRAX Chief Operating Officer?

The filing lists multiple stock options (rights to buy common stock), including grants for 11,999, 821, 9,999, 30,000, 36,400, and 22,500 shares, each with its own exercise price and vesting schedule.

What are some exercise prices of the PRAX stock options held by the COO?

The reported stock options have exercise prices including $257.25, $31.8, $44.4, $43.37, $56.94, and $63.15 per share of Praxis common stock.

How do the RSUs reported in the PRAX Form 3 vest for the COO?

The RSUs include 5,805 unvested RSUs from a July 29, 2024 grant that vests in equal annual installments over four years beginning January 12, 2025, and 11,250 RSUs from a January 10, 2025 grant vesting annually over four years beginning January 10, 2026.

Do the PRAX stock options reported by the COO have multi-year vesting schedules?

Yes. Several options vest over four-year periods, often with 25% vesting on an initial date (such as June 22, 2023, January 12, 2024, or January 10, 2026) and the remaining 75% in 36 monthly installments, subject to continued service.

Is any PRAX stock held indirectly or through another entity in this Form 3?

No. All reported common stock and stock options for Megan Sniecinski in this Form 3 are shown with direct (D) ownership and no separate indirect ownership entity is listed.